Drilldown: Medicines
Medicines > classes 
:
Antidepressant or
Dissociative or
[[:Category:Heart_failure_medications|Heart failure medication]]
:
Antidepressant or
Dissociative or
[[:Category:Heart_failure_medications|Heart failure medication]] Use the filters below to narrow your results.
generic:
brand:
None (18) ·
Anafranil (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
DXM (1) ·
DXO (1) ·
Edronax (1) ·
Farxiga (US), Forxiga (international) (1) ·
Fetzima (1) ·
Jardiance (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Parnate (1) ·
Savella (1) ·
Serzone (1) ·
Spravato (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (3) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Contains salvinorin A (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (37) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"' (1) ·
'"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"' (1)
starting dose:
None (37) ·
10 mg PO once daily in the morning; 5 mg starting in heart failure (1) ·
10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect (1) ·
25 mg (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
fda max:
onset:
None (36) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months (1) ·
Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Within hours of first administration (1)
duration:
halflife:
bioavailability:
None (36) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' (1) ·
~48% intranasal (1) ·
~50% (highly variable) (1) ·
~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1)
pregnancy:
None (36) ·
Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Avoid; may cause fetal harm (1) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1)
Showing below up to 41 results in range #1 to #41.